Retrospective Analysis of Direct-Acting Antiviral Treatment Outcomes in Hepatitis C Patients in Saudi Arabia Before and After Therapy - Report - MDSpire

Retrospective Analysis of Direct-Acting Antiviral Treatment Outcomes in Hepatitis C Patients in Saudi Arabia Before and After Therapy

  • By

  • Fatimah Salem Alayidh

  • Alexander Woodman

  • Nawaf Yahya Zakary

  • Rehab Yusuf Al-Ansari

  • Sharjeel Chaudhry

  • Amal Omar Alsaadi

  • Khadijah Ahmad Alharbi

  • Batool Abdullah Alamri

  • Shahad Mousa Alhomud

  • Shahad Hassan Albather

  • Sarah Abdullah Bataweel

  • Nouf Ahmed Madkhali

  • Samira Jamaan Alzahrani

  • Zarmina Ehtesham

  • February 2, 2026

  • 0 min

Share

Clinical Report: Direct-Acting Antiviral Treatment Outcomes in HCV Patients in Saudi Arabia

Overview

This study evaluates the real-world outcomes of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) patients in Saudi Arabia, highlighting sustained virologic response (SVR) rates and the impact of genotyping. The findings underscore the effectiveness of DAAs in achieving high cure rates and improving patient management.

Background

HCV infection is a significant global health issue, with serious complications including cirrhosis and hepatocellular carcinoma. The introduction of DAAs has transformed HCV treatment, offering higher cure rates compared to previous therapies. Understanding treatment outcomes in different populations is crucial for optimizing management strategies and achieving elimination goals.

Data Highlights

OutcomeRate
SVR1290%
SVR2485%

Key Findings

  • DAA therapy achieved SVR rates exceeding 90% among treated patients.
  • A significant proportion of patients had indeterminate HCV genotypes, impacting treatment decisions.
  • Real-world data supports the effectiveness of DAAs in diverse patient populations.
  • SVR significantly reduces the risk of liver-related complications and improves quality of life.
  • Continued monitoring for HCV-related complications is essential even after achieving SVR.

Clinical Implications

Healthcare providers should consider the high efficacy of DAAs in treating HCV and the importance of genotyping in treatment planning. Ongoing surveillance for liver-related complications post-SVR is critical to ensure comprehensive patient care.

Conclusion

The findings from this study reinforce the effectiveness of DAAs in achieving high cure rates for HCV in Saudi Arabia, while also highlighting the need for continued patient monitoring post-treatment.

References

  1. Journal of Gastroenterology, 2024 -- Histological Enhancement of Fibrosis in Hepatitis C Patients Achieving a Five-Year Sustained Virological Response Following Direct-Acting Antiviral Therapy
  2. Infection, 2024 -- Real-World Evidence on Direct Acting Antiviral Therapy for Hepatitis C in Individuals Who Inject Drugs or Receive Opioid Substitution Treatment
  3. Journal of Gastroenterology, 2026 -- Continuity of long-term follow-up in patients with chronic hepatitis C after sustained virologic response following direct-acting antiviral therapy: a nationwide real-world multicenter cohort study in Japan
  4. Journal of Gastroenterology, 2023 -- Liver Function After Treatment, Rather Than Initial Function, Predicts Survival in Patients with Decompensated Cirrhosis and Hepatitis C Virus Following Direct-Acting Antiviral Therapy
  5. HCV Guidance - Recommendations for Testing, Managing, and Treating Hepatitis C
  6. Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations - PubMed
  7. Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia - PMC
  8. HCV Guidance
  9. Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations
  10. Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia - PMC

Original Source(s)

Retrospective Analysis of Direct-Acting Antiviral Treatment Outcomes in Hepatitis C Patients in Saudi Arabia Before and After Therapy

  • by Fatimah Salem Alayidh, Alexander Woodman, Nawaf Yahya Zakary, Rehab Yusuf Al-Ansari, Sharjeel Chaudhry, Amal Omar Alsaadi, Khadijah Ahmad Alharbi, Batool Abdullah Alamri, Shahad Mousa Alhomud, Shahad Hassan Albather, Sarah Abdullah Bataweel, Nouf Ahmed Madkhali, Samira Jamaan Alzahrani, Zarmina Ehtesham

  • February 2, 2026

Related Content

Indiana community fights to keep needle exchange going after Trump order

Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies

Assessment of Liver Cancer Burden from 1990 to 2021 with Projections for 2040: Findings from the 2021 Global Burden of Disease Study